Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project

Susanne Doblecki-Lewis, Albert Liu, Daniel J Feaster, Stephanie E. Cohen, Gabriel Cardenas, Oliver Bacon, Erin Andrew, Michael A Kolber

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

ABSTRACT: Pre-exposure prophylaxis (PrEP) for prevention of HIV infection has demonstrated efficacy in randomized controlled trials as well as in demonstration projects. For PrEP implementation to result in significant reductions in HIV incidence for men who have sex with men (MSM) in the United States, sufficient access to PrEP care and continued engagement outside of demonstration projects is required. We report the results of a follow-up survey of 173 former participants from the Miami and San Francisco sites of the U.S. PrEP Demo Project, administered 4-6 months after study completion. Survey respondents continued to frequently access medical care and had a high incidence of sexually transmitted infections after completion of the Demo Project, indicating ongoing sexual risk behavior. Interest in continuing PrEP was high, with 70.8% indicating they were “very interested” in continuing PrEP. Among respondents, 39.9% reported continuation of PrEP following completion of the Demo Project, largely through their primary care providers and frequently at low or no cost. Variability in access and engagement was seen, with participants from the San Francisco site, those with medical insurance, and those with a primary care provider at the end of the Demo Project more likely to successfully obtain PrEP medication. Two respondents reported HIV seroconversion in the period between study completion and the follow-up survey. Additional effort to increase equitable access to PrEP outside of demonstration projects is needed to realize the potential impact of this evidence-based prevention intervention.

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
DOIs
StateAccepted/In press - Nov 14 2016

Fingerprint

San Francisco
Delivery of Health Care
Primary Health Care
HIV Seropositivity
Pre-Exposure Prophylaxis
Incidence
Sexually Transmitted Diseases
Risk-Taking
Insurance
Sexual Behavior
HIV Infections
Surveys and Questionnaires
Randomized Controlled Trials
HIV
Costs and Cost Analysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project. / Doblecki-Lewis, Susanne; Liu, Albert; Feaster, Daniel J; Cohen, Stephanie E.; Cardenas, Gabriel; Bacon, Oliver; Andrew, Erin; Kolber, Michael A.

In: Journal of Acquired Immune Deficiency Syndromes, 14.11.2016.

Research output: Contribution to journalArticle

@article{6f23e5dcec50434c9c7f705fc89c7976,
title = "Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project",
abstract = "ABSTRACT: Pre-exposure prophylaxis (PrEP) for prevention of HIV infection has demonstrated efficacy in randomized controlled trials as well as in demonstration projects. For PrEP implementation to result in significant reductions in HIV incidence for men who have sex with men (MSM) in the United States, sufficient access to PrEP care and continued engagement outside of demonstration projects is required. We report the results of a follow-up survey of 173 former participants from the Miami and San Francisco sites of the U.S. PrEP Demo Project, administered 4-6 months after study completion. Survey respondents continued to frequently access medical care and had a high incidence of sexually transmitted infections after completion of the Demo Project, indicating ongoing sexual risk behavior. Interest in continuing PrEP was high, with 70.8{\%} indicating they were “very interested” in continuing PrEP. Among respondents, 39.9{\%} reported continuation of PrEP following completion of the Demo Project, largely through their primary care providers and frequently at low or no cost. Variability in access and engagement was seen, with participants from the San Francisco site, those with medical insurance, and those with a primary care provider at the end of the Demo Project more likely to successfully obtain PrEP medication. Two respondents reported HIV seroconversion in the period between study completion and the follow-up survey. Additional effort to increase equitable access to PrEP outside of demonstration projects is needed to realize the potential impact of this evidence-based prevention intervention.",
author = "Susanne Doblecki-Lewis and Albert Liu and Feaster, {Daniel J} and Cohen, {Stephanie E.} and Gabriel Cardenas and Oliver Bacon and Erin Andrew and Kolber, {Michael A}",
year = "2016",
month = "11",
day = "14",
doi = "10.1097/QAI.0000000000001236",
language = "English (US)",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",

}

TY - JOUR

T1 - Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project

AU - Doblecki-Lewis, Susanne

AU - Liu, Albert

AU - Feaster, Daniel J

AU - Cohen, Stephanie E.

AU - Cardenas, Gabriel

AU - Bacon, Oliver

AU - Andrew, Erin

AU - Kolber, Michael A

PY - 2016/11/14

Y1 - 2016/11/14

N2 - ABSTRACT: Pre-exposure prophylaxis (PrEP) for prevention of HIV infection has demonstrated efficacy in randomized controlled trials as well as in demonstration projects. For PrEP implementation to result in significant reductions in HIV incidence for men who have sex with men (MSM) in the United States, sufficient access to PrEP care and continued engagement outside of demonstration projects is required. We report the results of a follow-up survey of 173 former participants from the Miami and San Francisco sites of the U.S. PrEP Demo Project, administered 4-6 months after study completion. Survey respondents continued to frequently access medical care and had a high incidence of sexually transmitted infections after completion of the Demo Project, indicating ongoing sexual risk behavior. Interest in continuing PrEP was high, with 70.8% indicating they were “very interested” in continuing PrEP. Among respondents, 39.9% reported continuation of PrEP following completion of the Demo Project, largely through their primary care providers and frequently at low or no cost. Variability in access and engagement was seen, with participants from the San Francisco site, those with medical insurance, and those with a primary care provider at the end of the Demo Project more likely to successfully obtain PrEP medication. Two respondents reported HIV seroconversion in the period between study completion and the follow-up survey. Additional effort to increase equitable access to PrEP outside of demonstration projects is needed to realize the potential impact of this evidence-based prevention intervention.

AB - ABSTRACT: Pre-exposure prophylaxis (PrEP) for prevention of HIV infection has demonstrated efficacy in randomized controlled trials as well as in demonstration projects. For PrEP implementation to result in significant reductions in HIV incidence for men who have sex with men (MSM) in the United States, sufficient access to PrEP care and continued engagement outside of demonstration projects is required. We report the results of a follow-up survey of 173 former participants from the Miami and San Francisco sites of the U.S. PrEP Demo Project, administered 4-6 months after study completion. Survey respondents continued to frequently access medical care and had a high incidence of sexually transmitted infections after completion of the Demo Project, indicating ongoing sexual risk behavior. Interest in continuing PrEP was high, with 70.8% indicating they were “very interested” in continuing PrEP. Among respondents, 39.9% reported continuation of PrEP following completion of the Demo Project, largely through their primary care providers and frequently at low or no cost. Variability in access and engagement was seen, with participants from the San Francisco site, those with medical insurance, and those with a primary care provider at the end of the Demo Project more likely to successfully obtain PrEP medication. Two respondents reported HIV seroconversion in the period between study completion and the follow-up survey. Additional effort to increase equitable access to PrEP outside of demonstration projects is needed to realize the potential impact of this evidence-based prevention intervention.

UR - http://www.scopus.com/inward/record.url?scp=84995770343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995770343&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001236

DO - 10.1097/QAI.0000000000001236

M3 - Article

C2 - 27861236

AN - SCOPUS:84995770343

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

ER -